AzTrials
AzTrials

CirrhosisEyeMTRACKIN-HENCT03732118

EYE-Mobile TRACKer IN the Diagnosis of Minimal Hepatic Encephalopathy

An observational study of Cirrhosis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Hepatic encephalopathy (HE) corresponds to the neurological or the neuropsychological symptoms caused by an acute or chronic liver disease and/or porto-systemic shunt. Many patients present neurological symptoms even if their liver disease is stabilized. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Cirrhosis
What is being tested?
Eye-tracker Mobile EBT
Type of treatment
Medical device
How many people
30 participants
Where
1 siteFrance
Study dates
18 Dec 2020to 17 Oct 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Subjects with cirrhosis

Who may be able to join

  • Eligibility criteria for EHM+ subjects:
  • Age between 18 and 70 (inclusive)
  • Cirrhosis
  • Minimal hepatic encephalopathy
  • Expression of non opposition
  • Eligibility criteria for EHM- subjects:
Show all 11Show fewer
  • Age between 18 and 70 (inclusive)
  • Cirrhosis
  • No hepatic encephalopathy (minimal or clinical)
  • Paired with EHM+ subjects about age, gender, MELD score and cirrhosis etiology
  • Expression of non opposition

Who cannot join

  • Age older than 70
  • MMS score < 24
  • Clinical hepatic encephalopathy
  • Cirrhosis etiology different from alcoholic, viral or metabolic one
  • Intake of psychotropic drugs within 48h
  • Alcohol intake > 30 g/j
Show all 13Show fewer
  • Heart, renal or respiratory failure
  • Evolutive neurological diseases
  • History of neurological diseases causing consequences
  • Non corrected visuals disorders
  • Oculomotor disorders from any etiology
  • Highly-resistant bacteria carrier subjects
  • Inability to put on the eye-tracker device

Trial locations and contacts

1 site in 1 country.

Nicolas WEISS, MD, PhD contact

+33(0)1 42 16 27 70

nicolas.weiss@aphp.fr

France1 site, 1 recruiting
  • Pitié-Salpêtrière Hospital

    Paris, 75013

    Nicolas WEISS, MD, PhD, + 33 (0)1 42 16 27 70, nicolas.weiss@aphp.fr

    Recruiting

Other trials in France

About this study

Hepatic encephalopathy (HE) corresponds to the neurological or the neuropsychological symptoms caused by an acute or chronic liver disease and/or porto-systemic shunt. Many patients present neurological symptoms even if their liver disease is stabilized. Furthermore, HE is associated with an altered quality of life and an increased mortality. Its incidence is high with 30 to 80% of cirrhotic patients that will display according to retained diagnostic criteria. HE symptoms are going from subtle neuropsychological abnormalities detected only on neuropsychological testing, minimal HE, to altered consciousness, overt HE. Recently, the therapeutic armamentarium has increased with now several drugs (rifaximin, ammonia lowering agents) that are able to prevent new bouts of HE. Unfortunately, the diagnosis of minimal HE is difficult and no gold-standard is available. None of the proposed test is rapid and easily performed at bedside.

Recently, different studies suggest the potential interest of the study of the ocular movements in HE. Abnormalities in ocular saccades could be an early predictor of cortical impairment. In a pilot feasibility study using an eye-tracker, we could show that cirrhotic patients with minimal HE had, compared to healthy controls, increased latencies, decreased speed of voluntary and reflex saccades, more errors in anti-saccades, more anticipations saccades and more difficulties to fix the target.

Read more

Our hypothesis was that the use of the eye-tracker will enable the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades.

Since no gold-standard is available for the diagnosis of minimal HE, we will use the conclusion of an adjudication committee formed by 2 experts. Their clinical judgment will take into account the results of medical history, clinical examination, neuropsychological testing, PHES, Critical Flicker Frequency test (CFF), ammonemia levels, EEG and brain MRI with spectroscopy.

Read the detailed description

Hepatic encephalopathy (HE) corresponds to the neurological or the neuropsychological symptoms caused by an acute or chronic liver disease and/or porto-systemic shunt. Many patients present neurological symptoms even if their liver disease is stabilized. Furthermore, HE is associated with an altered quality of life and an increased mortality. Its incidence is high with 30 to 80% of cirrhotic patients that will display according to retained diagnostic criteria. HE symptoms are going from subtle neuropsychological abnormalities detected only on neuropsychological testing, minimal HE, to altered consciousness, overt HE. Recently, the therapeutic armamentarium has increased with now several drugs (rifaximine, ammonia lowering agents) that are able to prevent new bouts of HE. Unfortunately, the diagnosis of minimal HE is difficult and no gold-standard is available. None of the proposed test is rapid and easily performed at bedside.

Recently, different studies suggest the potential interest of the study of the ocular movements in HE. Abnormalities in ocular saccads could be an early predictor of cortical impairment. In a pilot feasibility study using an eye-tracker, we could show that cirrhotic patients with minimal HE had, compared to healthy controls, increased latencies, decreased speed of voluntary and reflex saccads, more errors in anti-saccads, more anticipations saccads and more difficulties to fix the target.

Our hypothesis was that the use of the eye-tracker will enable the diagnosis of minimal HE by studying the characteristics of saccads and anti-saccads.

Since no gold-standard is available for the diagnosis of minimal HE, we will use the conclusion of an adjudication committee formed by 2 experts. Their clinical judgment will take into account the results of medical history, clinical examination, neuropsychological testing, PHES, Critical Flicker Frequency test (CFF), ammonemia levels, EEG and brain MRI with spectroscopy.

Gold standard definition: diagnostic of minimal HE as stated by adjudication committee composed of 2 experts. Each patient will be classified as : patient without EH (neither clinical or minimal) and patient with EHM. The results of medical history, clinical examination, EEG results (triphasic waves, decreased frequency), ammonia level (above 50mcmol/L or not), neuropsychological testing encompassing PHES (below -4 or not) and CFF (below 39Hz or not), brain MRI with MR-spectroscopy (HE profile on MRS) will be aggregated to obtain their adjudication. All the tests will be performed by trained personal aware of the evaluation of cirrhotic patients with possible HE. The eye-tracking evaluation will be blinded to the conclusion of the adjudication committee (presence or absence of HE).

Since the data from the eye-tracker are quantitative, a ROC curve will be used to evaluate the diagnostic performance of each parameters measured by the study device (mainly, saccads latencies, voluntary and reflexes ones, and the percentage of errors in saccads, anti-saccads and voluntary anticipations).

The ability of each measure to diagnose minimal HE will be evaluated by the area under the ROC and its 95% confidence interval. Sensibility, specificity, positive and negative predictive values will be given for each possible cut-off with their 95% confidence interval. In order to optimize the diagnostic performance, the most discriminating values will be used to build a multivariate diagnostic model. To prevent overfitting frequently associated with "standard" logistic regression, the selection of variables of interest will be performed with the LASSO method. This method is valuable when the number of subjects are limited.

Conditions
Cirrhosis
Being tested
Eye-tracker Mobile EBT
Medical subject headings
Fibrosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Eye-tracker Mobile EBTDevice

    Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.

Study groups in NCT03732118
Study groupRoleWhat they receive
Minimal hepatic encephalopathyNot described
Receives: Device: Eye-tracker Mobile EBT
No hepatic encephalopathy (minimal or clinical)Not described
Receives: Device: Eye-tracker Mobile EBT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic performance (evaluated with the area under the roc curve) associated with the measure of reflex saccads latencies for the diagnostic of minimal HE

    The diagnostic performance of the measure of reflex saccads latencies will be evaluated by the area under the roc curve and its 95% confidence interval

    Measured: one day

Secondary outcomes (14)
  1. Area under the roc curve associated with the measure of reflex saccads speed for the diagnostic of minimal HE.

    The diagnostic performance of the measure of reflex saccads speed will be evaluated by the area under the roc curve and its 95% confidence interval.

    Measured: one day

  2. Association between reflex saccads speed and results of neuropsychological testings

    Measured: one day

  3. Area under the roc curve associated with the measure of reflex saccads gain for the diagnostic of minimal HE

    The diagnostic performance of the measure of reflex saccads gain will be evaluated by the area under the roc curve and its 95% confidence interval.

    Measured: one day

  4. Association between reflex saccads gain and results of neuropsychological testings

    Measured: one day

  5. Area under the roc curve associated with the measure of voluntary saccads latency for the diagnostic of minimal HE.

    The diagnostic performance of the measure of voluntary saccads latency will be evaluated by the area under the roc curve and its 95% confidence interval.

    Measured: one day

  6. Association between voluntary saccads latency and results of neuropsychological testings

    Measured: one day

  7. Area under the roc curve associated with the measure of voluntary saccads gain for the diagnostic of minimal HE.

    The diagnostic performance of the measure of voluntary saccads gain will be evaluated by the area under the roc curve and its 95% confidence interval.

    Measured: one day

  8. Association between voluntary saccads gain and results of neuropsychological testings

    Measured: one day

  9. Area under the roc curve associated with the measure of voluntary saccads anticipation for the diagnostic of minimal HE.

    The diagnostic performance of the measure of voluntary saccads anticipation will be evaluated by the area under the roc curve and its 95% confidence interval.

    Measured: one day

  10. Association between voluntary saccads anticipation and results of neuropsychological testings

    Measured: one day

  11. Area under the roc curve associated with the measure of percentage of errors in saccads for the diagnostic of minimal HE.

    The diagnostic performance of the measure of percentage of errors in saccads will be evaluated by the area under the roc curve and its 95% confidence interval.

    Measured: one day

  12. Association between percentage of errors in saccads and results of neuropsychological testings

    Measured: one day

  13. Area under the roc curve associated with the measure of percentage of errors in anti-saccads for the diagnostic of minimal HE

    The diagnostic performance of the measure of percentage of errors in anti-saccads will be evaluated by the area under the roc curve and its 95% confidence interval.

    Measured: one day

  14. Association between percentage of errors in anti-saccads and results of neuropsychological testings

    Measured: one day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Nov 2018
  2. Study start18 Dec 2020
  3. Primary completion17 Oct 2023 (estimated)
  4. Study completion17 Oct 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03732118
Sponsor's protocol ID
NI17058J
Other IDs
2018-A02156-49
Acronym
EyeMTRACKIN-HE
Status last verified
Feb 2022
First submitted
22 Oct 2018
Last updated
15 Nov 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Cirrhosis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Nicolas WEISS, MD, PhD (+33(0)1 42 16 27 70, nicolas.weiss@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic performance (evaluated with the area under the roc curve) associated with the measure of reflex saccads latencies for the diagnostic of minimal HE (time frame: one day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in